Advertisement

Phenomenology of Atypical Parkinsonism

  • Steven J. FruchtEmail author
  • Pichet Termsarasab
Chapter
  • 39 Downloads

Abstract

Atypical parkinsonism includes three main disorders, progressive supranuclear palsy, multiple system atrophy, and corticobasal syndrome. Each of these disorders has a rich and distinct history in neurology, and clinical examination and management of these challenging patients requires careful attention to the movement disorder history and phenomenology.

Keywords

Progressive supranuclear palsy Multiple system atrophy Corticobasal syndrome Vertical supranuclear gaze palsy Dystonia Myoclonus Parkinsonism 

Supplementary material

Video 4.1

This chapter reviews the wide-ranging phenomenology of the three major forms of atypical parkinsonism: multiple system atrophy (MSA), including striatonigral degeneration (SND), Shy-Drager Syndrome (SDS), and olivopontocerebellar degeneration (OPCA); progressive supranuclear palsy (PSP); and corticobasal syndrome (CBS). Corticobasal degeneration is the most common cause of CBS; however because it is not possible to separate corticobasal degeneration from other causes of CBS (primary progressive aphasia, frontotemporal dementia) on clinical grounds, CBS better describes these patients. This video chapter is divided into eight segments: MSA, pure OPCA; MSA, SND-SDS-OPCA; MSA, unusual phenomena; PSP, early to mild; PSP, moderate to advanced; CBS, asymmetric mild to moderate; CBS, moderate to advanced; and CBS, unusual (MP4 7256229 kb)

References

  1. 1.
    Goetz CG. Charcot the clinician: the tuesday lessons. New York: Raven Press; 1987.Google Scholar
  2. 2.
    Charcot JM. Leçons du Mardi: Policlinique de la Salpêtrière, 1887–1888. Bureaux du Progrès Médical, Paris: Lesson of June 12, 1888.Google Scholar
  3. 3.
    Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol. 1964;10:333–59.  https://doi.org/10.1001/archneur.1964.00460160003001.CrossRefPubMedGoogle Scholar
  4. 4.
    Williams DR, Lees AJ, Wherrett JR, Steele JC. J. Clifford Richardson and 50 years of progressive supranuclear palsy. Neurology. 2008;70(7):566–73.  https://doi.org/10.1212/01.wnl.0000286938.39473.0e.CrossRefPubMedGoogle Scholar
  5. 5.
    Steele JC. Historical perspectives and memories of progressive supranuclear palsy. Semin Neurol. 2014;34(2):121–8.  https://doi.org/10.1055/s-0034-1381740.CrossRefPubMedGoogle Scholar
  6. 6.
    Richardson JC, Steele J, Olszewski J. Supranuclear ophthalmoplegia, pseudobulbar palsy, nuchal dystonia and dementia. A clinical report on eight cases of “heterogenous system degeneration”. Trans Am Neurol Assoc. 1963;88:25–9.PubMedGoogle Scholar
  7. 7.
    Olszewski J, Steele J, Richardson JC. Pathological report on six cases of heterogeneous system degeneration. J Neuropathol Exp Neurol. 1963;23:87–188.Google Scholar
  8. 8.
    Dickens C, Collins W. The lazy tour of two idle apprentices. London: Chapman & Hall; 1890.Google Scholar
  9. 9.
    Verhaart WJ. Degeneration of the brain stem reticular formation, other parts of the brain stem and the cerebellum; an example of heterogenous systemic degeneration of the central nervous system. J Neuropathol Exp Neurol. 1958;17(2):382–91.  https://doi.org/10.1097/00005072-195804000-00021.CrossRefPubMedGoogle Scholar
  10. 10.
    Neumann MA. Heterogeneous system degeneration with particular involvement of the reticular substance: correlation with neurologic disorders and the concept of the Creutzfeld-Jakob disease. J Neuropathol Exp Neurol. 1961;20:316.Google Scholar
  11. 11.
    Chavany JA, van Bogaert L, Godlewski S. Sur un syndrome de rigidité a predominance axiale, avec perturbation des automatismes oculopalpebraux d’origine encephalitique. Presse Med. 1951;59:958–62.PubMedGoogle Scholar
  12. 12.
    Brusa A. Degenerescence plurisystematisee du nevraxe, de charactere sporadique, a debut tardif et evolution subaigue. Rev Neurol (Paris). 1961;104:412–29.Google Scholar
  13. 13.
    Barbeau A. Degenerescence plurisystematisee du nevraxe. Syndrome de Steele-Richardson-Olszewski. Un Med Can. 1965;94:715–8.Google Scholar
  14. 14.
    Mailliot C, Sergeant N, Bussiere T, Caillet-Boudin ML, Delacourte A, Buee L. Phosphorylation of specific sets of tau isoforms reflects different neurofibrillary degeneration processes. FEBS Lett. 1998;433(3):201–4.  https://doi.org/10.1016/s0014-5793(98)00910-7.CrossRefPubMedGoogle Scholar
  15. 15.
    Dejerine J, Thomas AA. L’atrophie olivo-ponto-cérébelleuse. Nouv Iconog de la Salpêtrière. 1900;13:330–70.Google Scholar
  16. 16.
    Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension: a clinical-pathologic study. Arch Neurol. 1960;2:511–27.  https://doi.org/10.1001/archneur.1960.03840110025004.CrossRefPubMedGoogle Scholar
  17. 17.
    Adams RD, van Bogaert L, van der Eecken H. Dégénérescences nigro-striées et cerebello-nigro-striées. Psychiatr Neurol. 1961;142:219–59.CrossRefGoogle Scholar
  18. 18.
    Bradbury S, Eggleston C. Postural hypotension. A report of three cases. Am Heart J. 1925;1:73–86.CrossRefGoogle Scholar
  19. 19.
    Graham JG, Oppenheimer DR. Orthostatic hypotension and nicotine sensitivity in a case of multiple system atrophy. J Neurol Neurosurg Psychiatry. 1969;32(1):28–34.  https://doi.org/10.1136/jnnp.32.1.28.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Quinn N. Multiple system atrophy – the nature of the beast. J Neurol Neurosurg Psychiatry. 1989;52(Suppl):78–89.  https://doi.org/10.1136/jnnp.52.suppl.78.CrossRefGoogle Scholar
  21. 21.
    van der Eecken H, Adams RD, van Bogaert L. Striopallidal-nigral degeneration. An hitherto undescribed lesion in paralysis agitans. J Neuropathol Exp Neurol. 1960;19:159–61.Google Scholar
  22. 22.
    Quinn N. A short clinical history of multiple system atrophy. Clin Auton Res. 2015;25(1):3–7.  https://doi.org/10.1007/s10286-014-0265-7.CrossRefPubMedGoogle Scholar
  23. 23.
    Bannister R, Oppenheimer DR. Degenerative diseases of the nervous system associated with autonomic failure. Brain. 1972;95(3):457–74.  https://doi.org/10.1093/brain/95.3.457.CrossRefPubMedGoogle Scholar
  24. 24.
    Papp MI, Kahn JE, Lantos PL. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J Neurol Sci. 1989;94(1–3):79–100.  https://doi.org/10.1016/0022-510x(89)90219-0.CrossRefPubMedGoogle Scholar
  25. 25.
    Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997;388(6645):839–40.  https://doi.org/10.1038/42166.CrossRefPubMedGoogle Scholar
  26. 26.
    Spillantini MG, Crowther RA, Jakes R, Cairns NJ, Lantos PL, Goedert M. Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson’s disease and dementia with Lewy bodies. Neurosci Lett. 1998;251(3):205–8.  https://doi.org/10.1016/s0304-3940(98)00504-7.CrossRefPubMedGoogle Scholar
  27. 27.
    Wenning GK, Stefanova N, Jellinger KA, Poewe W, Schlossmacher MG. Multiple system atrophy: a primary oligodendrogliopathy. Ann Neurol. 2008;64(3):239–46.  https://doi.org/10.1002/ana.21465.CrossRefPubMedGoogle Scholar
  28. 28.
    Rebeiz JJ, Kolodny EH, Richardson EP Jr. Corticodentatonigral degeneration with neuronal achromasia. Arch Neurol. 1968;18(1):20–33.  https://doi.org/10.1001/archneur.1968.00470310034003.CrossRefPubMedGoogle Scholar
  29. 29.
    Dutil A. Sur un cas de paralysie agitante à forme hemiplégique avec attitude anormale de la tête et du tronc (extension). Nouvelle Iconographie de la Salpêtrière. 1889;2:165–9.Google Scholar
  30. 30.
    Goetz CG, Chmura TA, Lanska DJ. Parkinsonism-plus syndromes: part 7 of the MDS-sponsored history of movement disorders exhibit, Barcelona, June 2000. Mov Disord. 2001;16(3):541.CrossRefGoogle Scholar
  31. 31.
    Ballan G, Tison F. A historical case of probable corticobasal degeneration? Mov Disord. 1997;12(6):1073–4.  https://doi.org/10.1002/mds.870120639.CrossRefPubMedGoogle Scholar
  32. 32.
    Lhermitte J, Lévy G, Kyriaco N. Les perturbations de la representation spatial chez les apraxiques. Rev Neurol (Paris). 1925;2:586–600.Google Scholar
  33. 33.
    Funkenstein HH, Miller DC. Case records of the Massachusetts General Hospital. Case 38-1985 — a 66-year-old man with progressive neurologic deterioration. N Engl J Med. 1985;313:739–48.CrossRefGoogle Scholar
  34. 34.
    Gibb WR, Luthert PJ, Marsden CD. Corticobasal degeneration. Brain. 1989;112(Pt 5):1171–92.  https://doi.org/10.1093/brain/112.5.1171.CrossRefPubMedGoogle Scholar
  35. 35.
    Riley DE, Lang AE, Lewis A, Resch L, Ashby P, Hornykiewicz O, et al. Cortical-basal ganglionic degeneration. Neurology. 1990;40(8):1203–12.  https://doi.org/10.1212/wnl.40.8.1203.CrossRefPubMedGoogle Scholar
  36. 36.
    Boeve BF, Maraganore DM, Parisi JE, Ahlskog JE, Graff-Radford N, Caselli RJ, et al. Pathologic heterogeneity in clinically diagnosed corticobasal degeneration. Neurology. 1999;53(4):795–800.  https://doi.org/10.1212/wnl.53.4.795.CrossRefPubMedGoogle Scholar
  37. 37.
    Kertesz A, Davidson W, Munoz DG. Clinical and pathological overlap between frontotemporal dementia, primary progressive aphasia and corticobasal degeneration: the Pick complex. Dement Geriatr Cogn Disord. 1999;10 Suppl 1:46–9.  https://doi.org/10.1159/000051212.CrossRefPubMedGoogle Scholar
  38. 38.
    Wenning GK, Litvan I, Tolosa E. Milestones in atypical and secondary Parkinsonisms. Mov Disord. 2011;26(6):1083–95.  https://doi.org/10.1002/mds.23713.CrossRefPubMedGoogle Scholar
  39. 39.
    Houlden H, Baker M, Morris HR, MacDonald N, Pickering-Brown S, Adamson J, et al. Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology. 2001;56(12):1702–6.  https://doi.org/10.1212/wnl.56.12.1702.CrossRefPubMedGoogle Scholar
  40. 40.
    Lewy F. Paralysis agitans. I. Pathologische Anatomie. In: Lewandowsky M, Abelsdorff G, editors. Handbuch der Neurologie, vol. 3. Berlin: Springer; 1912. p. 920–33.Google Scholar
  41. 41.
    Goedert M, Spillantini MG, Del Tredici K, Braak H. 100 years of Lewy pathology. Nat Rev Neurol. 2013;9(1):13–24.  https://doi.org/10.1038/nrneurol.2012.242.CrossRefPubMedGoogle Scholar
  42. 42.
    Tretiakoff C. Contribution à l’étude de l’anatomie pathologique du locus niger de Soemmering avec quelques déductions relatives à la pathogénie des troubles du tonus musculaire et de la maladie de Parkinson. [Thesis]: University of Paris; 1919.Google Scholar
  43. 43.
    Okazaki H, Lipkin LE, Aronson SM. Diffuse intracytoplasmic ganglionic inclusions (Lewy type) associated with progressive dementia and quadriparesis in flexion. J Neuropathol Exp Neurol. 1961;20:237–44.  https://doi.org/10.1097/00005072-196104000-00007.CrossRefPubMedGoogle Scholar
  44. 44.
    Hansen L, Salmon D, Galasko D, Masliah E, Katzman R, DeTeresa R, et al. The Lewy body variant of Alzheimer’s disease: a clinical and pathologic entity. Neurology. 1990;40(1):1–8.  https://doi.org/10.1212/wnl.40.1.1.CrossRefPubMedGoogle Scholar
  45. 45.
    McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 1996;47(5):1113–24.  https://doi.org/10.1212/wnl.47.5.1113.CrossRefPubMedGoogle Scholar
  46. 46.
    McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65(12):1863–72.  https://doi.org/10.1212/01.wnl.0000187889.17253.b1.CrossRefPubMedGoogle Scholar
  47. 47.
    McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2017;89(1):88–100.  https://doi.org/10.1212/WNL.0000000000004058.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30(12):1591–601.  https://doi.org/10.1002/mds.26424.CrossRefPubMedGoogle Scholar
  49. 49.
    Boeve BF, Dickson DW, Duda JE, Ferman TJ, Galasko DR, Galvin JE, et al. Arguing against the proposed definition changes of PD. Mov Disord. 2016;31(11):1619–22.  https://doi.org/10.1002/mds.26721.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    O’Keeffe FM, Murray B, Coen RF, Dockree PM, Bellgrove MA, Garavan H, et al. Loss of insight in frontotemporal dementia, corticobasal degeneration and progressive supranuclear palsy. Brain. 2007;130(Pt 3):753–64.  https://doi.org/10.1093/brain/awl367.CrossRefPubMedGoogle Scholar
  51. 51.
    Maher ER, Lees AJ. The clinical features and natural history of the Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology. 1986;36(7):1005–8.  https://doi.org/10.1212/wnl.36.7.1005.CrossRefPubMedGoogle Scholar
  52. 52.
    Ling H. Clinical approach to progressive supranuclear palsy. J Mov Disord. 2016;9(1):3–13.  https://doi.org/10.14802/jmd.15060.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Fanciulli A, Wenning GK. Multiple-system atrophy. N Engl J Med. 2015;372(3):249–63.  https://doi.org/10.1056/NEJMra1311488.CrossRefPubMedGoogle Scholar
  54. 54.
    Palma JA, Fernandez-Cordon C, Coon EA, Low PA, Miglis MG, Jaradeh S, et al. Prevalence of REM sleep behavior disorder in multiple system atrophy: a multicenter study and meta-analysis. Clin Auton Res. 2015;25(1):69–75.  https://doi.org/10.1007/s10286-015-0279-9.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Parmera JB, Rodriguez RD, Studart Neto A, Nitrini R, Brucki SMD. Corticobasal syndrome: a diagnostic conundrum. Dement Neuropsychol. 2016;10(4):267–75.  https://doi.org/10.1590/s1980-5764-2016dn1004003.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain. 2002;125(Pt 2):391–403.  https://doi.org/10.1093/brain/awf033.CrossRefPubMedGoogle Scholar
  57. 57.
    Urwyler P, Nef T, Muri R, Archibald N, Makin SM, Collerton D, et al. Visual hallucinations in eye disease and Lewy body disease. Am J Geriatr Psychiatry. 2016;24(5):350–8.  https://doi.org/10.1016/j.jagp.2015.10.007.CrossRefPubMedGoogle Scholar
  58. 58.
    Termsarasab P, Thammongkolchai T, Rucker JC, Frucht SJ. The diagnostic value of saccades in movement disorder patients: a practical guide and review. J Clin Mov Disord. 2015;2:14.  https://doi.org/10.1186/s40734-015-0025-4.CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Quinn N. The “round the houses” sign in progressive supranuclear palsy. Ann Neurol. 1996;40(6):951.  https://doi.org/10.1002/ana.410400630.CrossRefPubMedGoogle Scholar
  60. 60.
    Yoon WT, Chung EJ, Lee SH, Kim BJ, Lee WY. Clinical analysis of blepharospasm and apraxia of eyelid opening in patients with parkinsonism. J Clin Neurol. 2005;1(2):159–65.  https://doi.org/10.3988/jcn.2005.1.2.159.CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Greene P. Progressive supranuclear palsy, corticobasal degeneration, and multiple system atrophy. Continuum (Minneap Minn). 2019;25(4):919–35.  https://doi.org/10.1212/CON.0000000000000751.CrossRefGoogle Scholar
  62. 62.
    Dubois B, Slachevsky A, Pillon B, Beato R, Villalponda JM, Litvan I. “Applause sign” helps to discriminate PSP from FTD and PD. Neurology. 2005;64(12):2132–3.  https://doi.org/10.1212/01.WNL.0000165977.38272.15.CrossRefPubMedGoogle Scholar
  63. 63.
    Armstrong MJ. Progressive supranuclear palsy: an update. Curr Neurol Neurosci Rep. 2018;18(3):12.  https://doi.org/10.1007/s11910-018-0819-5.CrossRefPubMedGoogle Scholar
  64. 64.
    Watanabe H, Saito Y, Terao S, Ando T, Kachi T, Mukai E, et al. Progression and prognosis in multiple system atrophy: an analysis of 230 Japanese patients. Brain. 2002;125(Pt 5):1070–83.  https://doi.org/10.1093/brain/awf117.CrossRefPubMedGoogle Scholar
  65. 65.
    Wenning GK, Ben Shlomo Y, Magalhaes M, Daniel SE, Quinn NP. Clinical features and natural history of multiple system atrophy. An analysis of 100 cases. Brain. 1994;117(Pt 4):835–45.  https://doi.org/10.1093/brain/117.4.835.CrossRefPubMedGoogle Scholar
  66. 66.
    Isozaki E, Naito A, Horiguchi S, Kawamura R, Hayashida T, Tanabe H. Early diagnosis and stage classification of vocal cord abductor paralysis in patients with multiple system atrophy. J Neurol Neurosurg Psychiatry. 1996;60(4):399–402.  https://doi.org/10.1136/jnnp.60.4.399.CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Ozawa T, Sekiya K, Aizawa N, Terajima K, Nishizawa M. Laryngeal stridor in multiple system atrophy: clinicopathological features and causal hypotheses. J Neurol Sci. 2016;361:243–9.  https://doi.org/10.1016/j.jns.2016.01.007.CrossRefPubMedGoogle Scholar
  68. 68.
    Thompson PD. Myoclonus in corticobasal degeneration. Clin Neurosci. 1995;3(4):203–8.PubMedGoogle Scholar
  69. 69.
    Rinne JO, Lee MS, Thompson PD, Marsden CD. Corticobasal degeneration. A clinical study of 36 cases. Brain. 1994;117(Pt 5):1183–96.  https://doi.org/10.1093/brain/117.5.1183.CrossRefPubMedGoogle Scholar
  70. 70.
    Hassan A, Whitwell JL, Josephs KA. The corticobasal syndrome-Alzheimer’s disease conundrum. Expert Rev Neurother. 2011;11(11):1569–78.  https://doi.org/10.1586/ern.11.153.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Division of Movement DisordersNew York University Grossman School of Medicine, The Marlene and Paolo Fresco Institute for Parkinson’s and Movement Disorders, NYU Langone HealthNew YorkUSA
  2. 2.Division of Neurology, Faculty of MedicineRamathibodi Hospital, Mahidol UniversityBangkokThailand

Personalised recommendations